Effects of apolipoproteins on dalargin transport across the blood-brain barrier

Bulletin of Experimental Biology and Medicine

Volumn 142, Issue 6, 2006, Pages 703-706

  Shamenkov, D A ^a   Petrov, V E ^a   Alyautdin, R N ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Apolipoprotein B; Apolipoprotein E; Blood brain barrier; Dalargin; Nanoparticles

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; CLUSTERIN; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; NANOCARRIER; POLY(BUTYL)CYANOACRYLATE; POLYSORBATE 80; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; MOUSE; NONHUMAN; TAIL FLICK TEST;

ADSORPTION; ANALGESICS; ANIMALS; ANIMALS, OUTBRED STRAINS; APOLIPOPROTEINS B; APOLIPOPROTEINS E; BEHAVIOR, ANIMAL; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; COATED MATERIALS, BIOCOMPATIBLE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENBUCRILATE; ENKEPHALIN, LEUCINE-2-ALANINE; MICE; NANOPARTICLES; PARTICLE SIZE; POLYSORBATES; TIME FACTORS;

MUS;

EID: 34147116890     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-006-0456-x     Document Type: Article

References (15)

1. R. Alyautdin, D. Gothier, V. Petrov, et al., Eur. J. Pharm. Biopharm., 41, 44-48 (1995).
2. R. Alyautdin, V. E. Petrov, K. Langer, et al., Pharm. Res., 14, 325-328 (1997).
3. D. J. Begley, J. Pharm. Pharmacol., 48, 136-146 (1996).
4. H. Davson and M. Segal, Physiology of the CSF and Blood-Brain Barrier, Boca Raton (1996), pp. 1-192.
5. B. Dehouck, M. P. Dehouck, J. C. Fruchart, and R. Cecchelli, J. Cell. Biol., 126, 465-473 (1994).
6. B. Dehouck, L. Fenart, M.-P. Dehouck, et al., Ibid., 138, 877-889 (1997).
7. L. Fenart, A. Casanova, B. Dehouck, et al., J. Pharmacol. Exp. Ther., 291, 1017-1022 (1999).
8. J. Kreuter and R. Alyautdin, The Blood-Brain Barrier and Drug Delivery to the CNS, Eds. D. J. Begley et al., New York (2000), pp. 205-223.
9. J. Kreuter, R. Alyautdin, D. A. Kharkevich, and A. A. Ivanov, Brain Res., 674, 171-174 (1995).
10. J. Kreuter, V. E. Petrov, D. A. Kharkevich, and R. Alyautdin, J. Control. Release, 49, 81-87 (1997).
11. A. Minn, R. D. S. El-Bacha, C. Bayol-Denizot, et al., The Blood-Brain Barrier and Drug Delivery to the CNS, Eds. D. J. Begley et al., New York (2000), pp. 145-170.
12. P. Ramge, R. E. Unger, B. Oltrogge, et al., Eur. J. Neurosci., 12, 1931-1940 (2000).
13. U. Schroeder and B. A. Sabel, Brain Res., 710, 121-124 (1996).
14. U. Schroeder, P. Sommerfeld, and B. A. Sabel, Peptides, 19, 777-780 (1998).
15. U. Schroeder, P. Sommerfeld, S. Ulrich, and B. A. Sabel, J. harm. Sci., 87, 1305-1307 (1998).